Next Article in Journal
Central Pain Due to Injury of the Spinothalamic Tract Misdiagnosed as Complex Regional Pain Syndrome: A Case Report
Previous Article in Journal
Increased Serum Parathyroid Hormone, Osteocalcin and Alkaline Phosphatase Are Associated with a Long-Term Adverse Cardiovascular Outcome after Coronary Artery Bypass Graft Surgery
Previous Article in Special Issue
Very Early Response Evaluation by PET/MR in Patients with Lung Cancer—Timing and Feasibility
Open AccessArticle

Improved Quantification of 18F-FDG PET during 131I-Rituximab Therapy on Mouse Lymphoma Models after 131I Prompt Emission Correction

by Young Sub Lee 1,2, Hee-Joung Kim 3 and Jin Su Kim 1,4,*
1
Division of RI Application, Korea Institute Radiological and Medical Sciences, Seoul 01812, Korea
2
Division of Radiation Regulation, Department of Medical Radiation Safety, Korea Institute of Nuclear Safety, Daejeon 34142, Korea
3
Department of Radiation Convergence Engineering and Research Institute of Health Science, Yonsei University, Wonju 26493, Korea
4
Radiological and Medico-Oncological Sciences, University of Science and Technology, Seoul 01812, Korea
*
Author to whom correspondence should be addressed.
Diagnostics 2019, 9(4), 144; https://doi.org/10.3390/diagnostics9040144
Received: 17 September 2019 / Accepted: 7 October 2019 / Published: 8 October 2019
(This article belongs to the Special Issue Imaging of Early Response in Cancer Management 2019)
18F-FDG Positron Emission Tomography (PET) is used to monitor tumor response to 131I-therapy, but is confounded by prompt emissions (284, 364, 637, and 723 keV) from 131I, particularly in animal PET imaging. We propose a method for correcting this emission in 18F-FDG PET. The 131I prompt emission effect was assessed within various energy windows and various activities. We applied a single gamma correction method to a phantom and in vivo mouse model. The 131I prompt emission fraction was 12% when 300 µCi of 131I and 100 µCi of FDG were administered, and increased exponentially with escalating 131I activity for all energy windows. The difference in spill-over ratio was reduced to <5% after 131I prompt emission correction. In the mouse model, the standard uptake value (SUV) did not differ significantly between FDG PET only (gold standard) and FDG PET after 131I prompt emission-correction, whereas it was overestimated by 38% before correction. Contrast was improved by 18% after 131I prompt emission correction. We first found that count contamination on 18F-FDG follow-up scans due to 131I spilled-over count after 131I rituximab tumor targeted therapy. Our developed 131I prompt emission-correction method increased accuracy during measurement of standard uptake values on 18F-FDG PET. View Full-Text
Keywords: 18F-FDG PET; personalized medicine; 131I prompt emission-correction; radioimmunotherapy; rituximab; rituxan 18F-FDG PET; personalized medicine; 131I prompt emission-correction; radioimmunotherapy; rituximab; rituxan
Show Figures

Figure 1

MDPI and ACS Style

Lee, Y.S.; Kim, H.-J.; Kim, J.S. Improved Quantification of 18F-FDG PET during 131I-Rituximab Therapy on Mouse Lymphoma Models after 131I Prompt Emission Correction. Diagnostics 2019, 9, 144.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop